You may have heard about a recall of varenicline. This medicine may not be right for pregnant women, people who have seizures, people who have eating disorders, or heavy alcohol users. It may help with withdrawal symptoms and the urge to smoke. Check with your insurance plan to see if you are covered.īupropion SR (e.g., Wellbutrin), is a medicine without nicotine. Many insurance plans cover quit smoking medications. You'll need a prescription from your doctor to get these medications. There are two common prescription medications that help smokers quit: Bupropion SR and Varenicline. NRT is available over the counter and by prescription. However, research shows that NRT is safe and works. Some smokers have mild to moderate side effects. This small amount of nicotine helps satisfy cravings for nicotine and reduces your urge to smoke. NRT doesn't have any of the other dangerous chemicals found in cigarettes. NRT works by giving you a small, controlled amount of nicotine, which is the main addictive substance in cigarettes and other tobacco products. Your pharmacist or doctor can help you choose which is best for you. There are 7 FDA approved medications (5 NRT products: patch, lozenge, gum, nasal spray, and inhaler and 2 prescription medications: Bupropion and Varenicline). What medications and NRT products are available? Follow instructions carefully to get the most benefit. But they are just one type of tool, not a magic bullet. Many former smokers find that using these medications for a couple of months helped them quit. The agency agreed to voluntary corrective action in that case as well.īoth of those decisions came after GAO partially sustained a pre-award protest arguing the procurement unfairly disadvantaged large companies in mentor-protégé arrangements in November 2021.Medications can make it easier to quit smoking by reducing cravings and withdrawal symptoms. GAO previously dismissed 117 complaints in November 2022 over the use of a points based scoring system used to analyze prior performance of the entities bidding. In March, the GAO dismissed a round of bid protests after the agency agreed to voluntary corrective action to make a new phase one determination on highest rated offerors. They’ve been both dismissed and sustained, as the agency pushes forward with the solicitation. Those challenges have focused on the process and criteria by which the awarding agency was using to select awardees. The CIO-SP4 vehicle has a $50 billion ceiling.Įntities seeking inclusion in National Institutes of Health Information Technology Acquisition and Assessment Center (NITAAC)’s 10-year solicitation have made multiple challenges through bid protests over the last two years. Protests filed by entities not represented by counsel will be addressed in a separate, forthcoming decision, Patton added.ĬIO-SP4 is the fourth iteration of a contract vehicle for acquiring commoditized IT products and specialized services that has been dogged by pre-award protests since the agency first requested proposals in May 2021. It addressed protests by entities represented by outside counsel who were eligible for a protective order. The decision was issued under a protective order because it “may contain proprietary and source selection sensitive information,” according to Patton. GAO denied remaining arguments the protesters raised, which included challenges to other aspects of the evaluations and untimely challenges, he said. Patton also said the GAO found the agency “unreasonably evaluated specific aspects” of a phase one proposal from Sky Solutions LLC. “GAO recommended that the agency reevaluate proposals consistent with the decision, and make new determinations of which proposals advance past phase 1 of the competition based on the results of these new evaluations,” Patton said, echoing previous statements from the organization. Patton said the agency’s decision to not advance those proposals was “flawed”, citing NIH’s inability to show that it both reasonably evaluated phase one proposals and determined which would move on to the next stages of the competition. In a Thursday statement, managing associate general counsel for procurement law at GAO Kenneth E. The Government Accountability Office sustained 98 legal challenges to National Institutes of Health’s embattled solicitation, CIO-SP4, concluding that the agency “unreasonably failed” to advance proposals by 64 entities past the first phase on their evaluation.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |